Vesugen

What Vesugen does

Vesugen is a synthetic three-amino-acid peptide studied for blood flow, aging markers and salivary-gland problems. Small Russian reports leave benefits hard to separate from other treatments; safety, absorption and injection doses remain poorly defined. No registered trial was found.

• In a small study of people with poor blood flow in the legs, authors saw better clinical and scan results; a clear benefit is not established. (Studied in a trial)
• Studied in small reports for erectile problems; one described better blood flow to the penis, but the paper has inconsistencies. (Studied in a trial)
• In small studies, people taking it with Pinealon had changes in biological age markers, but no longer life was shown. (Studied in a trial)
• Studied alongside other treatments for dry mouth and salivary gland problems; its own share of any benefit is unknown. (Studied in a trial)

Uses in the sources

• Studied for blood flow in leg arteries and erectile dysfunction in small reports. Clear clinical benefit has not been established. (Studied in a trial) (source)
• Small reports measured biological-age indicators. They did not show longer life. (Studied in a trial) (source)
• Studied within combination regimens for salivary-gland disease and dry mouth. Peptide-only benefit is unknown. (Studied in a trial) (source)

Vesugen dosage

Typical reported dose: 1 mg once a day

• One capsule twice daily: 1 capsule twice daily with food; peptide mass unstated. twice daily, by mouth. Studied in a trial. Studied in: Adults aged 61-75 with salivary injury after chemotherapy. (source)
• One-month salivary-gland regimen: 1 capsule twice daily; peptide mass unstated. twice daily, by mouth. Studied in a trial. Studied in: Adults aged 61-81 with chronic salivary-gland inflammation. (source)
• Discharge advice: two courses yearly: 1 capsule orally twice daily with food for 30 days; peptide mass unstated. twice daily, by mouth. Clinician-published. Studied in: Older adults in the combination-care group after hospital discharge. (source)
• One tablet three times daily: 1 tablet three times daily; peptide mass unstated. three times daily, by mouth. Studied in a trial. Studied in: 69 adults aged 61-85 with chronic salivary-gland disease. (source)
• One milligram daily report: 1 mg once daily. once daily, under the skin. Reported by users, rare report. Studied in: Adults in online discussions; frequency in the wider community is unknown. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Vesugen

Comes as: Oral capsules and tablets in human reports., Community-reported powder vials and nasal spray..

Mixed with: No diluent or mixing volume was verified from an acceptable noncommercial source..

• The reported nasal solution was 2 mg/mL, not a 2 mg delivered dose.
• Do not convert capsule mass or animal doses into injection doses.
• Common vial sizes and mixing volumes remain unverified; no preparation recipe is provided.

Before mixing: No validated compound-specific temperature or shelf life was located.

After mixing: No validated mixed-vial stability or beyond-use period was located.

Vesugen side effects and risks

Reported side effects

• Allergic or injection-related reactions: No compound specific rate is established. These are general risks of unapproved peptide products., serious. Stop use and seek care for a spreading reaction or signs of infection. (source)
• Other short- and long-term effects: No reliable adverse event denominator is available., moderate. Report new symptoms and the exact product, dose, route and timing. (source)
• Prooxidant and blood-cell-marker changes: One 32 person report noted increased oxidation signals and lower circulating CD34+ cells; no rates or clinical harms were quantified., moderate. Discuss unexplained bruising, infection or fatigue and whether a blood count is needed. (source)

Stop and get help if

• Trouble breathing, throat swelling, widespread hives or collapse: Call emergency services now; these may be signs of anaphylaxis.
• Fever with confusion, rapid breathing or a very painful spreading injection-site infection: Get emergency care now; severe infection can progress quickly.
• Sudden face droop, one-sided weakness, speech trouble or vision loss: Call emergency services now, even if symptoms improve. These can be stroke signs.
• Chest pressure or pain with shortness of breath, sweating or lightheadedness: Call emergency services now for possible heart attack.

Who should avoid it

• pregnant: Precaution: no reliable pregnancy safety data for this peptide.
• breastfeeding: Precaution: transfer into milk and infant effects are unknown.
• tryingToConceive: Precaution: fertility and early-pregnancy effects are unknown.
• under18: Precaution: no reliable pediatric safety evidence was located.
• kidneyDisease: Clearance and dose adjustment in kidney disease are unknown.
• liverDisease: No liver-disease dose or safety study was located.
• testedAthlete: The 2026 S0 rule is expected to prohibit this unapproved substance at all times.
• activeCancer: Precaution: KED alters cell-growth and IGF1 signals in culture. Effects on tumor growth in people are unknown.
• cancerHistory: Small post-cancer dental reports do not establish recurrence safety.
• bleedingDisorder: Patent claims include changes in clotting tests; effects on bleeding and thrombosis are unconfirmed.
• heartCondition: Small vascular reports do not show protection from heart attack or stroke.

Interactions

• Anticoagulants and antiplatelet drugs: Interaction unstudied. Patent clotting-test changes make combined use a precaution, not a proven interaction.
• Cyclophosphamide: KED reduced cyclophosphamide growth suppression in rat tissue culture. Whether this affects cancer therapy is unknown.
• Other experimental bioregulators and recovery peptides: Small reports and forum stacks cannot establish interaction safety or attribute effects to one peptide.

Product quality risks

• No independent published market-testing study specific to this peptide was located.
• General peptide warnings describe wrong strength, wrong ingredients and microbial contamination.
• An online semaglutide study found low purity and endotoxin. This does not measure contamination in this peptide.

What to expect

12 clinical papers and 2 patent examples found. Reports may include the same participants; these are not 14 independent trials.

Key studies

• Truck drivers and stress: Combined Pinealon and Vesugen had the strongest reported changes in stress-related questionnaire scores. (source)
• Blood flow after leg-artery surgery: Authors reported better clinical and ultrasound measures after Vesugen. (source)
• Vascular report with conflicting indexing: The abstract reports improved penile blood flow; the title and abstract do not match. (source)
• Older adults with several illnesses: Aging-marker changes came with prooxidant activity and fewer circulating CD34+ cells. (source)
• Work-ability index report: Combined cytogens reportedly improved work-ability measures; Vesugen-specific effects cannot be isolated. (source)
• Comparison of aging interventions: Vesugen plus Pinealon had the strongest reported changes in biological-age indicators. (source)

Vesugen FAQ

• Is Vesugen FDA-approved? No approved product or dose label found. No compound-specific PCAC decision or FDA warning letter was located.
• How do people take it? Under the skin, once daily. Reported at day 20; planned end not stated.. Source: reported by users, not an established dose.
• What's the difference between Vesugen and Pinealon? Vesugen: an experimental blood-vessel peptide with unclear benefits and poorly defined safety. Pinealon: a peptide with unproven brain benefits and no established injection dose. Why people pair them: used together for aging or brain-related goals; small human reports cannot establish the value of adding it.
• Can I take it with Pinealon? Used together for aging or brain-related goals; small human reports cannot establish the value of adding it. No controlled human combination study located. Safety and added benefit are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Inference from the S0 non-approved-substance rule; neither peptide is named individually. No therapeutic approval was located.
• How long does a mixed vial last? No validated mixed-vial stability or beyond-use period was located.